Watched quite a bit of the video, but its getting to be bed
Watched quite a bit of the video, but its getting to be bed time for me, so brief synopsis of what I heard.
Dr. BP said they are analyzing results of the randomized trials of patients even though they don't know who got what, and the results so far look very good...so that must be telling of they can almost tell who did and didn't get leronlimab is my guess from looking at blood samples?
Also near the 51 minute mark went on a small controlled rant about Dr. Fauci and remdesivir saying he is a very smart man, but used words like Remdesivir was "trending" when you can't write a scientific peer reviewed journal on trending data, you need concrete evidence something is working and remdesivir hasn't had anyone explain how it works. An anti-viral that doesn't lower the viral load, but patients seem to stay less days in the hospital.
Also interesting, their COVID findings showing things they didn't know before and that maybe leronlimab does more than just block HIV...it might actually start attacking it in the body with that cell thing that is like a bullet(sorry the name and spelling escape me...I'm not a scientist).
Dr. Yo went on a bit of a rant wondering why people are just doing the hydroxy or remdesivir in the medical community and refusing to listen to him about leronlimab. Dr. BP said if he was to ever get COVID he'd carry around a bottle of leronlimab in his pocket if Nader would let him :o)
Some good stuff. There were things he hadn't looked into like Dr. Mike is on to the ACE2 receptor where the virus first attaches, and Dr. BP states that he has not dug into everything, but the one thing consistent in all patients for sure is elevated rantes, so he does agree there are other things unexplored in the early stages, but we already know leronlimab is not a preventative medicine anyway.
Sorry, probably too long of a post but its a 1 hr and 20 minute video and much more I didn't cover, but things that stuck out to me. Happy sleeping all !
7
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...
Continue Reading
Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...
Continue Reading
Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...
Continue Reading
Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...
Continue Reading
Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...
Continue Reading
Top 5 Most Recently Viewed Articles
Top Revenue Generating Mobile and CTV Apps for December 2024 The evolving landscape of mobile and Connected TV (CTV) applications continually captivates users and advertisers alike. As 2024 comes to a close, the spotlight shines on the highest-grossing apps in North America, specifically in the United States and Canada, revealing significant trends in user engagement and...
Continue Reading
Introduction to LET Mining's New Approach LET Mining is making waves with its innovative strategy that leverages XRP for cloud mining. This fresh perspective has caught the attention of numerous XRP holders, sparking excitement about its long-term profit potential. As more users join the platform, LET Mining is focusing on refining its computing power allocation to...
Continue Reading
Understanding American Intl Gr's Short Interest Dynamics American Intl Gr (AIG) has recently seen a notable change in its short percent of float, which has decreased by 3.24% since the last report. This change reflects a current total of 10.23 million shares sold short, making up approximately 1.79% of all available shares for trading. With the current trading volume,...
Continue Reading
The Rising Phosphate Market: An Overview The phosphate market is experiencing remarkable growth, projected to soar to approximately $219.74 billion in the coming years, driven by an annual growth rate of 3.9%. This growth is closely linked to the rising global demand for agricultural fertilizers, which play a crucial role in providing essential nutrients for plants....
Continue Reading
Clene Inc. to Engage with Investors at Benchmark Conference Clene Inc. (Nasdaq: CLNN), a dynamic clinical-stage biopharmaceutical company, is making its mark in the healthcare industry by focusing on innovative solutions for neurodegenerative diseases. Their mission is clear: to enhance mitochondrial health and safeguard neuronal functions. With a commitment to tackling...
Continue Reading